Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiyanping Injection in Pediatric Bronchitis
NCT02937857Phase 4Unknown
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Aug 2016
- Primary completion
- Apr 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of andrographolide sulfonate in bronchitis (2 arms), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoint: Time to total score of the clinical symptoms/signs decreased more than 70% from baseline up to 30 days. Status: unknown.
02
Drugs
andrographolide sulfonate
03
Conditions
bronchitis
Beyond the preview
Go deeper on NCT02937857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937857.